Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Plasma cell 1Lymphoid 1

Conditions

Leukemia 4Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma 1Leukemia, Myeloid, Accelerated Phase 1Hodgkin Disease 1Blast Crisis 1

Interventions

Azacitidine 38Cytarabine 22venetoclax 19fludarabine phosphate 18fludarabine 18Cyclophosphamide 18Peripheral Blood Stem Cell Transplantation 15Tacrolimus 14Filgrastim 13Decitabine 13Mycophenolic Acid 12Busulfan 12Whole-Body Irradiation 11Melphalan 11Methotrexate 10Cyclosporine 10Antilymphocyte Serum 8Stem Cell Transplantation 7Alemtuzumab 7decitabine and cedazuridine drug combination 6Granulocyte Colony-Stimulating Factor 6Clofarabine 6AP 1903 reagent 6Thiotepa 5Rituximab 5Idarubicin 5quizartinib 4Tretinoin 4Sirolimus 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Myelodysplastic Syndromes × Methylprednisolone Acetate × Clear all
NCT02464657 2021-10-07

Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center

Phase 1/2 Completed
44 enrolled 12 charts
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01875237 2019-07-16

Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene

M.D. Anderson Cancer Center

Phase 1/2 Terminated
3 enrolled 15 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡